


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T13:52:34Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12407652" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12407652</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>futoncol</setSpec>
        
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Future Oncol</journal-id><journal-id journal-id-type="iso-abbrev">Future Oncol</journal-id><journal-id journal-id-type="pmc-domain-id">3069</journal-id><journal-id journal-id-type="pmc-domain">futoncol</journal-id><journal-title-group><journal-title>Future Oncology</journal-title></journal-title-group><issn pub-type="ppub">1479-6694</issn><issn pub-type="epub">1744-8301</issn><publisher><publisher-name>Taylor &amp; Francis</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12407652</article-id><article-id pub-id-type="pmcid-ver">PMC12407652.1</article-id><article-id pub-id-type="pmcaid">12407652</article-id><article-id pub-id-type="pmcaiid">12407652</article-id><article-id pub-id-type="pmid">40772783</article-id><article-id pub-id-type="doi">10.1080/14796694.2025.2542030</article-id><article-id pub-id-type="publisher-id">2542030</article-id><article-version-alternatives><article-version article-version-type="pmc-version">1</article-version><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" vocab-term="Version of Record" article-version-type="VoR">Version of Record</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Patterns of treatment in first and subsequent lines in RCC in Spain. A real-world descriptive cross-sectional study</article-title><alt-title alt-title-type="left-running-head">J. A. ARRANZ ET AL.</alt-title><alt-title alt-title-type="right-running-head">FUTURE ONCOLOGY</alt-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Arranz</surname><given-names initials="JA">Jos&#233; A.</given-names></name><xref rid="aff0001" ref-type="aff">
<sup>a</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mart&#237;nez</surname><given-names initials="C">Cristina</given-names></name><xref rid="aff0002" ref-type="aff">
<sup>b</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gallego</surname><given-names initials="L">Luc&#237;a</given-names></name><xref rid="aff0003" ref-type="aff">
<sup>c</sup>
</xref><xref rid="an0001" ref-type="corresp"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Heredero</surname><given-names initials="A">Ana</given-names></name><xref rid="aff0002" ref-type="aff">
<sup>b</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Rebollo</surname><given-names initials="P">Pablo</given-names></name><xref rid="aff0003" ref-type="aff">
<sup>c</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Fern&#225;ndez</surname><given-names initials="L">Laura</given-names></name><xref rid="aff0004" ref-type="aff">
<sup>d</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Estella</surname><given-names initials="E">Elvira</given-names></name><xref rid="aff0005" ref-type="aff">
<sup>e</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Vilanova Larena</surname><given-names initials="D">David</given-names></name><xref rid="aff0006" ref-type="aff">
<sup>f</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Palomar</surname><given-names initials="V">Virginia</given-names></name><xref rid="aff0004" ref-type="aff">
<sup>d</sup>
</xref></contrib><aff id="aff0001"><label>a</label>Department of Medical Oncology, <institution-wrap><institution>Hospital General Universitario Gregorio Mara&#241;&#243;n</institution></institution-wrap>, <city>Madrid</city>, <country>Spain</country></aff><aff id="aff0002"><label>b</label>Department of Oncology, <institution-wrap><institution>IQVIA</institution></institution-wrap>, <city>Madrid</city>, <country>Spain</country></aff><aff id="aff0003"><label>c</label>Department of Real-World Evidence, <institution-wrap><institution>IQVIA</institution></institution-wrap>, <city>Madrid</city>, <country>Spain</country></aff><aff id="aff0004"><label>d</label>Department of Medical Affairs, <institution-wrap><institution>Bristol Myers Squibb</institution></institution-wrap>, <city>Madrid</city>, <country>Spain</country></aff><aff id="aff0005"><label>e</label>Department of Market Access, <institution-wrap><institution>Bristol Myers Squibb</institution></institution-wrap>, <city>Madrid</city>, <country>Spain</country></aff><aff id="aff0006"><label>f</label>Real World Evidence and Outcomes Research, Market Access Departement, <institution-wrap><institution>Bristol Myers Squibb</institution></institution-wrap>, <city>Madrid</city>, <country>Spain</country></aff></contrib-group><author-notes><corresp id="an0001">CONTACT Luc&#237;a Gallego <email xlink:href="mailto:lucia.gallego@iqvia.com">lucia.gallego@iqvia.com</email> Department of Real-World Evidence, IQVIA, <addr-line>C/Juan Esplandi&#250; 11 - 13, 6&#170;</addr-line>, <city>Madrid</city>, <country>Spain</country></corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>7</day><month>8</month><year>2025</year></pub-date><pub-date date-type="collection" publication-format="electronic"><year>2025</year></pub-date><volume>21</volume><issue>21</issue><issue-id pub-id-type="pmc-issue-id">496179</issue-id><fpage seq="8">2767</fpage><lpage>2774</lpage><pub-history><event event-type="pmc-release"><date><day>07</day><month>08</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 16:25:19.050"><day>04</day><month>09</month><year>2025</year></date></event><event event-type="tagger"><event-desc>Integra</event-desc><date><day>20</day><month>8</month><year>2025</year></date></event><event event-type="final"><event-desc>Integra</event-desc><date><day>20</day><month>8</month><year>2025</year></date></event><event event-type="received"><date><day>10</day><month>4</month><year>2025</year></date></event><event event-type="accepted"><date><day>29</day><month>7</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 The Author(s). Published by Informa UK Limited, trading as Taylor &amp; Francis Group.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>The Author(s)</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="IFON_21_2542030.pdf"/><self-uri content-type="pdf" xlink:href="IFON_21_2542030.pdf"/><abstract><title>ABSTRACT</title><sec><title>Aim</title><p>Advanced renal cell carcinoma (RCC) has had limited treatment options and poor prognosis. Initially, tyrosine kinase inhibitors (TKIs) increased progression-free survival (PFS) and allowed the identification of favorable (FP), intermediate (IP) and poor prognosis (PP) subgroups. While TKIs remain an option for FP patients, combinations of immune checkpoint inhibitors (IO) plus TKI in the overall population, or IO/IO in IP/PP patients, have improved overall survival (OS), and have become the standard of care. However, their adoption in clinical practice varies across countries.</p></sec><sec><title>Method</title><p>We conducted a cross-sectional observational study using Oncology Dynamics&#8482; database to assess treatment patterns in Spain.</p></sec><sec><title>Results</title><p>A total of 1,587 metastatic RCC (mRCC) patients were registered, 900 in first-line treatment for clear cell mRCC (mccRCC). In 2022, among mccRCC FP patients treated by oncologists (N&#8201;=&#8201;137), 92.7% received TKIs; while IP/PP patients (N&#8201;=&#8201;298), 56.7% received TKIs, 27.5% antiPD1-antiCTLA4, and 13.8% antiPD1-TKI. In 2023, mccRCC FP patients (N&#8201;=&#8201;124) received 94.4% TKIs; and IP/PP patients (N&#8201;=&#8201;256) received 48.4% TKIs, 38.3% antiPD1-antiCTLA4, and 12.1% antiPD1-TKI.</p></sec><sec><title>Conclusions</title><p>During this period, the uptake of IO/IO and IO/TKI in clinical practice in Spain was lower than expected according to current recommendations.</p></sec></abstract><kwd-group kwd-group-type="author"><title>KEYWORDS</title><kwd>Oncology</kwd><kwd>advanced renal cell carcinoma</kwd><kwd>tyrosine kinase inhibitors</kwd><kwd>immunotherapy</kwd><kwd>real-world evidence</kwd><kwd>clinical practice</kwd><kwd>nivolumab</kwd><kwd>oncology dynamics</kwd></kwd-group><support-group><funding-group><award-group><funding-source><institution-wrap><institution>Bristol Myers Squibb (BMS)</institution></institution-wrap></funding-source></award-group><funding-statement>Financial support for this study was provided by Bristol Myers Squibb (BMS).</funding-statement></funding-group></support-group><counts><fig-count count="2"/><table-count count="4"/><ref-count count="26"/><page-count count="8"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" disp-level="1" id="s0001"><label>1.</label><title>Introduction</title><p>Kidney cancer ranks as the 13th most common form of cancer globally, accounting for approximately 2.4% of all cancer cases [<xref rid="cit0001" ref-type="bibr">1</xref>]. In Spain, the estimated incidence for 2024 stands at 9,208 new cases, with 6,160 cases expected among males and 3,048 among females [<xref rid="cit0002" ref-type="bibr">2</xref>].</p><p>Renal Cell Carcinoma (RCC) represents the most common type of kidney cancer in adults, constituting nearly 85% of all primary renal neoplasms [<xref rid="cit0003" ref-type="bibr">3</xref>]. RCC originates in the lining of the renal tubules and presents a variety of histological subtypes, each with unique characteristics and prevalence. The clear cell subtype is the most common, occurring in approximately 75% of all RCC cases [<xref rid="cit0004" ref-type="bibr">4</xref>]. Each subtype possesses distinct characteristics and prevalence rates, contributing to the intricate nature of renal cell carcinoma.</p><p>At the time of diagnosis, approximately 25% of RCC patients present metastatic disease, and up to 20% of those treated for early-stage disease will experience recurrence [<xref rid="cit0005" ref-type="bibr">5</xref>]. To effectively manage advanced/metastatic RCC (mRCC), the International Metastatic renal cell carcinoma Database Consortium (IMDC) score is currently used as prognostic index to stratify patients with into three prognostic categories: favorable, intermediate and poor (FP, IP and PP, respectively). Each prognostic category is associated with different survival outcomes. Notably, up to 60% of patients with mRCC receiving first-line (1&#8201;L) treatment are classified in the IP group according to IMDC classification [<xref rid="cit0006" ref-type="bibr">6</xref>].</p><p>Treatment of mRCC has traditionally focused on targeting the vascular endothelial growth factor (VEGF) pathway through the use of tyrosine kinase inhibitors (TKIs) such as sorafenib, sunitinib, pazopanib, axitinib, cabozantinib, and lenvatinib; as well as anti-VEGF monoclonal antibodies like bevacizumab [<xref rid="cit0007" ref-type="bibr">7</xref>]. However, the treatment of mRCC has undergone a dramatic evolution over the last decade with the advent of immune checkpoint inhibitors (IO) targeting programmed cell death&#8211;1 protein (PD-1) such as nivolumab or pembrolizumab; as well as anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) such as ipilimumab. These agents have shown superior outcomes compared to tyrosine kinase inhibitor and mechanistic Target of Rapamycin (mTOR) inhibitor therapies in mRCC clinical trials.</p><p>In 2019, the European Medicines Agency (EMA) approved the combination of nivolumab and ipilimumab for treatment-na&#239;ve mRCC patients with IMDC IP and PP, based on the phase III CheckMate 214 trial. Long-term follow-up data from the phase III CheckMate 214 trial demonstrated that this combination offered long-term survival and more durable response benefits compared to sunitinib in these subpopulations of mRCC patients [<xref rid="cit0008" ref-type="bibr">8</xref>]. This led to the approval and reimbursement of this indication by the Spanish healthcare system [<xref rid="cit0009" ref-type="bibr">9</xref>]. In 2021, the EMA also approved the combination of nivolumab plus cabozantinib for 1&#8201;L treatment of mRCC. However, this indication is not yet reimbursed in Spain [<xref rid="cit0010" ref-type="bibr">10</xref>].</p><p>In this evolving therapeutic context, the introduction of IO-based combinations has redefined the standard of care for 1&#8201;L mRCC, significantly improving key clinical outcomes. However, real-world data are needed to assess the implementation of these therapies in routine clinical practice. This study aims to describe current treatment patterns for mRCC in Spain, providing insight into the adoption of novel therapies in routine care. Given the predominance of clear cell mRCC (mccRCC) within the patient population, our analysis will specifically focus on this subgroup, aiming to provide a comprehensive overview of treatment trends and their impacts.</p></sec><sec disp-level="1" id="s0002"><label>2.</label><title>Methods</title><p>This cross-sectional study was designed to elucidate the patterns of antineoplastic medical treatment administered to patients diagnosed with mRCC across first and subsequent lines of therapy, stratified by the IMDC prognostic groups as reported by clinicians which include favorable, intermediate and poor prognostic. Additionally, the study aimed to analyze variations in treatment based on other variables such as histological type (clear cell versus non-clear cell RCC), demographics and clinical characteristics of the patients, and specialty of the treating physician (oncologists versus urologists in the case of RCC).</p><p>The study received ethical approval from the Ethics Committee of the Hospital Cl&#237;nic in Spain, ensuring adherence to ethical standards in the conduct of research. Data for this study were obtained from the Oncology Dynamics&#8482; database managed by IQVIA. This is a comprehensive, syndicated, cross-sectional, multi-country dataset that collects anonymized patient-level data from a representative sample of cancer-treating physicians through structured electronic case report forms (eCRFs) completed during routine clinical visits. No personally identifiable information was collected, ensuring patient confidentiality.</p><p>The inclusion criteria for the study encompassed patients with a confirmed diagnosis of mRCC as recorded in the patient&#8217;s medical records, either through free text or using the disease code C64 as per the ICD-10 classification. The study population consisted of patients who were undergoing pharmacological treatment for advanced/metastatic disease (both first-line and subsequent lines) in Spain, during the period from 1 January 2022, to 31 December 2023. The variables analyzed in this study were extensive and included the current pharmacological treatment, the medical specialty of the treating physician, the line of treatment, the IMDC prognostic group (favorable, intermediate, and poor), gender, age range, current performance status as measured using the Eastern Cooperative Oncology Group (ECOG) scale, histological subtype of RCC (clear cell, non-clear cell), sites of metastasis, and comorbidities.</p><p>All statistical analyses adhered to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines and relevant sections of the Consolidated Standards of Reporting Trials (CONSORT) guidelines. Continuous variables were described using mean, standard deviation, median, minimum, and maximum values. Categorical variables were described using frequencies and percentages. The pharmacological treatments administered to patients were detailed for the total sample and stratified according to the line of treatment, employing counts and proportions. Furthermore, patients were categorized based on specific clinical characteristics such as risk category (favorable, intermediate, and poor), and their clinical management was described in a similar detailed manner. Given the descriptive nature of this study, there was no predefined hypothesis, and consequently, no formal calculation of sample size or statistical power was conducted. This approach ensured a comprehensive and nuanced understanding of the current treatment landscapes and their alignment with clinical guidelines and patient needs in the management of mRCC.</p></sec><sec disp-level="1" id="s0003"><label>3.</label><title>Results</title><p>A total of 1,587 patients diagnosed with mRCC were included in the analysis, with 801 cases reported in 2022 and 786 in 2023. Most patients (89.4%) were managed and treated by oncologists, while the remaining 10.6% were managed by urologists. The majority of patients were male, accounting for 63.6% of all mRCC patients. The age distribution showed a young demographic, with 51.1% of patients being younger than 65&#8201;years. Furthermore, a significant majority, 88.9%, exhibited a good Eastern Cooperative Oncology Group (ECOG) performance status ranging from 0 to 1. Histologically, clear cell carcinoma was identified in 75.1% of the cases, with non-clear cell and unspecified histology accounting for 10.5% and 14.4%, respectively. According to the IMDC classification, 30.2% of patients receiving 1&#8201;L treatment were classified as having favorable prognosis, 37% intermediate and 32.8%.</p><p>At the time of data collection 77.1% of patients (N&#8201;=&#8201;1,224) were receiving 1&#8201;L treatment and the rest second (2&#8201;L) or subsequent lines (N&#8201;=&#8201;363). <xref rid="t0001" ref-type="table">Table 1</xref> summarizes the main demographic and clinical characteristics of the study population, stratified by line of treatment. Lung was the most frequent site of metastasis, observed in 59.4% of patients in the 1&#8201;L group and 75.8% in the 2&#8201;L+ group. Most patients were male (63.8% in 1&#8201;L and 62.8% in 2&#8201;L+), younger than 65&#8201;years (52.7% in 1&#8201;L and 45.7% in 2&#8201;L+) and had a good performance status (ECOG 0&#8211;1: 88.3% in 1&#8201;L and 90.6% in 2&#8201;L+). Regarding comorbidities, 40.9% of patients in the 1&#8201;L group and 39.4% in the 2&#8201;L+ group had no registered comorbidities, indicating that approximately 60% of patients in both groups had at least one comorbidity.<table-wrap position="float" id="t0001" orientation="portrait"><label>Table 1.</label><caption><p>Demographic and clinical characteristics of the whole population by line of treatment.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col width="1*" align="left" span="1"/><col width="1*" align="center" span="1"/><col width="1*" align="center" span="1"/></colgroup><thead><tr><th align="left" colspan="1" rowspan="1">&#160;</th><th align="center" colspan="1" rowspan="1">Patients currently in 1&#8201;L</th><th align="center" colspan="1" rowspan="1">Patients currently 2&#8201;L+</th></tr><tr><th align="left" colspan="1" rowspan="1">&#160;</th><th align="center" colspan="1" rowspan="1">N&#8201;=&#8201;1224</th><th align="center" colspan="1" rowspan="1">N&#8201;=&#8201;363</th></tr></thead><tbody><tr><td colspan="3" align="left" rowspan="1"><bold>Gender, n (%)</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">Female</td><td align="center" colspan="1" rowspan="1">443 (36.19%)</td><td align="center" colspan="1" rowspan="1">135 (37.19%)</td></tr><tr><td align="left" colspan="1" rowspan="1">Male</td><td align="center" colspan="1" rowspan="1">781 (63.81%)</td><td align="center" colspan="1" rowspan="1">228 (62.81%)</td></tr><tr><td colspan="3" align="left" rowspan="1"><bold>Age, n (%)</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">&#8804;65&#8201;years</td><td align="center" colspan="1" rowspan="1">645 (52.70%)</td><td align="center" colspan="1" rowspan="1">166 (45.73%)</td></tr><tr><td align="left" colspan="1" rowspan="1">66&#8211;80&#8201;years</td><td align="center" colspan="1" rowspan="1">524 (42.81%)</td><td align="center" colspan="1" rowspan="1">187 (51.52%)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8201;&gt;&#8201;80&#8201;years</td><td align="center" colspan="1" rowspan="1">55 (4.49%)</td><td align="center" colspan="1" rowspan="1">10 (2.75%)</td></tr><tr><td colspan="3" align="left" rowspan="1"><bold>Performance status (ECOG) n (%)</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">ECOG 0&#8211;1</td><td align="center" colspan="1" rowspan="1">1081 (88,32%)</td><td align="center" colspan="1" rowspan="1">329 (90.63%)</td></tr><tr><td align="left" colspan="1" rowspan="1">ECOG &#8805;2</td><td align="center" colspan="1" rowspan="1">143 (11.68%)</td><td align="center" colspan="1" rowspan="1">34 (9.37%)</td></tr><tr><td colspan="3" align="left" rowspan="1"><bold>IMDC prognostic subgroups, n (%)</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">Favorable</td><td align="center" colspan="1" rowspan="1">370 (30.23%)</td><td align="center" colspan="1" rowspan="1">141 (38.84%)</td></tr><tr><td align="left" colspan="1" rowspan="1">Intermediate</td><td align="center" colspan="1" rowspan="1">453 (37.01%)</td><td align="center" colspan="1" rowspan="1">165 (45.45%)</td></tr><tr><td align="left" colspan="1" rowspan="1">Poor</td><td align="center" colspan="1" rowspan="1">401 (32.76%)</td><td align="center" colspan="1" rowspan="1">57 (15.70%)</td></tr><tr><td colspan="3" align="left" rowspan="1"><bold>Histology, n (%)</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">Clear cell</td><td align="center" colspan="1" rowspan="1">900 (73.53%)</td><td align="center" colspan="1" rowspan="1">292 (80.44%)</td></tr><tr><td align="left" colspan="1" rowspan="1">Non-clear cell</td><td align="center" colspan="1" rowspan="1">133 (10.87%)</td><td align="center" colspan="1" rowspan="1">33 (9.09%)</td></tr><tr><td align="left" colspan="1" rowspan="1">NOS</td><td align="center" colspan="1" rowspan="1">191 (15.60%)</td><td align="center" colspan="1" rowspan="1">38 (10.47%)</td></tr><tr><td colspan="3" align="left" rowspan="1"><bold>Metastasic sites, n (%)*</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">Lung</td><td align="center" colspan="1" rowspan="1">727 (59.40%)</td><td align="center" colspan="1" rowspan="1">275 (75.76%)</td></tr><tr><td align="left" colspan="1" rowspan="1">Liver</td><td align="center" colspan="1" rowspan="1">270 (22.06%)</td><td align="center" colspan="1" rowspan="1">87 (23.97%)</td></tr><tr><td align="left" colspan="1" rowspan="1">Bone</td><td align="center" colspan="1" rowspan="1">279 (22.79%)</td><td align="center" colspan="1" rowspan="1">81 (22.31%)</td></tr><tr><td align="left" colspan="1" rowspan="1">Lymph nodes</td><td align="center" colspan="1" rowspan="1">494 (40.36%)</td><td align="center" colspan="1" rowspan="1">167 (46.01%)</td></tr><tr><td align="left" colspan="1" rowspan="1">Brain</td><td align="center" colspan="1" rowspan="1">25 (2.04%)</td><td align="center" colspan="1" rowspan="1">4 (1.10%)</td></tr><tr><td colspan="3" align="left" rowspan="1"><bold>Comorbidities, n (%)**</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">Diabetes</td><td align="center" colspan="1" rowspan="1">271 (22.14%)</td><td align="center" colspan="1" rowspan="1">78 (21.49%)</td></tr><tr><td align="left" colspan="1" rowspan="1">COPD</td><td align="center" colspan="1" rowspan="1">201 (16.42%)</td><td align="center" colspan="1" rowspan="1">58 (15.98%)</td></tr><tr><td align="left" colspan="1" rowspan="1">Renal dysfunction</td><td align="center" colspan="1" rowspan="1">115 (9.40%)</td><td align="center" colspan="1" rowspan="1">42 (11.57%)</td></tr><tr><td align="left" colspan="1" rowspan="1">Cardiac dysfunction</td><td align="center" colspan="1" rowspan="1">87 (7.11%)</td><td align="center" colspan="1" rowspan="1">22 (6.06%)</td></tr><tr><td align="left" colspan="1" rowspan="1">Atrial fibrillation</td><td align="center" colspan="1" rowspan="1">78 (6.37%)</td><td align="center" colspan="1" rowspan="1">21 (5.79%)</td></tr><tr><td align="left" colspan="1" rowspan="1">None</td><td align="center" colspan="1" rowspan="1">501 (40.93%)</td><td align="center" colspan="1" rowspan="1">143 (39.39%)</td></tr></tbody></table><table-wrap-foot><fn id="tfn0001"><p>COPD, Chronic Obstructive Pulmonary Disease; ECOG, Eastern Cooperative Oncology Group; IMDC, International Metastatic renal cell carcinoma Database Consortium; NOS, Not otherwise specified.</p></fn><fn id="tfn0002"><p>Top 4 locations &amp; brain site of metastasis. **Top 5 comorbidities.</p></fn></table-wrap-foot></table-wrap></p><p><xref rid="t0002" ref-type="table">Table 2</xref> shows in detail the characteristics of the 1,198 patients who received one of the three primary types of 1&#8201;L treatments for RCC &#8211; TKI monotherapy, IO/IO combinations, or IO/TKI combinations &#8211; and the different clinical and demographic characteristics of the patients. At the time of analysis, patients in the favorable IMDC group were mostly treated with TKI monotherapy, which was the most used treatment in patients with FP (91.8%). Notably, 95.3% of these patients had ECOG 0&#8211;1. Less expectedly, TKI monotherapy we found that was also the most used treatment among the 831 IP/PP patients (63.8%), while the remaining IP/PP patients were currently receiving a combination of IO/IO (25%) or IO/TKI (11.2%). The data does not suggest that the choice of a monotherapy TKI was driven by any other patient characteristics, such as the presence and location of visceral metastases or the presence of comorbidities.<table-wrap position="float" id="t0002" orientation="portrait"><label>Table 2.</label><caption><p>Patient profile of 1&#8201;L patients treated with TKI or combinations IO/IO or TKI/IO (N&#8201;=&#8201;1198, other therapies excluded).</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col width="1*" align="left" span="1"/><col width="1*" align="center" span="1"/><col width="1*" align="center" span="1"/><col width="1*" align="center" span="1"/><col width="1*" align="char" char="." span="1"/><col width="1*" align="char" char="." span="1"/><col width="1*" align="char" char="." span="1"/></colgroup><thead><tr><th align="left" colspan="1" rowspan="1">&#160;</th><th colspan="3" align="center" rowspan="1">Favorable prognosis (N: 367, 30.6%)<hr/></th><th colspan="3" align="center" char="." rowspan="1">Intermediate/Poor prognosis (N: 831, 69,3%)<hr/></th></tr><tr><th align="left" colspan="1" rowspan="1">&#160;</th><th align="center" colspan="1" rowspan="1">IO/IO</th><th align="center" colspan="1" rowspan="1">IO/TKI</th><th align="center" colspan="1" rowspan="1">TKI</th><th align="center" char="." colspan="1" rowspan="1">IO/IO</th><th align="center" char="." colspan="1" rowspan="1">IO/TKI</th><th align="center" char="." colspan="1" rowspan="1">TKI</th></tr><tr><th align="left" colspan="1" rowspan="1">&#160;</th><th align="center" colspan="1" rowspan="1">N&#8201;=&#8201;16 (4.4%)</th><th align="center" colspan="1" rowspan="1">N&#8201;=&#8201;14 (3.8%)</th><th align="center" colspan="1" rowspan="1">N&#8201;=&#8201;337 (91.8%)</th><th align="char" char="." colspan="1" rowspan="1">N&#8201;=&#8201;208 (25.0%)</th><th align="char" char="." colspan="1" rowspan="1">N&#8201;=&#8201;93 (11.2%)</th><th align="char" char="." colspan="1" rowspan="1">N&#8201;=&#8201;530 (63,8%)</th></tr></thead><tbody><tr><td colspan="7" align="left" rowspan="1"><bold>Age ranges, n (%)</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;&#8804;65</td><td align="center" colspan="1" rowspan="1">11 (68.8%)</td><td align="center" colspan="1" rowspan="1">12 (85.7%)</td><td align="center" colspan="1" rowspan="1">146 (43.3%)</td><td align="char" char="." colspan="1" rowspan="1">158(75,96%)</td><td align="char" char="." colspan="1" rowspan="1">61(65,59%)</td><td align="char" char="." colspan="1" rowspan="1">246(46,42%)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;66&#8211;80</td><td align="center" colspan="1" rowspan="1">5 (31.25%)</td><td align="center" colspan="1" rowspan="1">2 (14.3%)</td><td align="center" colspan="1" rowspan="1">177 (52.5%)</td><td align="char" char="." colspan="1" rowspan="1">49(23,56%)</td><td align="char" char="." colspan="1" rowspan="1">32(34,41%)</td><td align="char" char="." colspan="1" rowspan="1">245(46,23%)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;&#8201;&gt;&#8201;80</td><td align="center" colspan="1" rowspan="1">0(0,00%)</td><td align="center" colspan="1" rowspan="1">0(0,00%)</td><td align="center" colspan="1" rowspan="1">14(4.15%)</td><td align="char" char="." colspan="1" rowspan="1">1(0,48%)</td><td align="char" char="." colspan="1" rowspan="1">0(0,00%)</td><td align="char" char="." colspan="1" rowspan="1">39(7,36%)</td></tr><tr><td colspan="7" align="left" rowspan="1"><bold>Gender, n (%)</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Female</td><td align="center" colspan="1" rowspan="1">10 (62.5%)</td><td align="center" colspan="1" rowspan="1">5 (35.7%)</td><td align="center" colspan="1" rowspan="1">119 (35.3%)</td><td align="char" char="." colspan="1" rowspan="1">63(30,29%)</td><td align="char" char="." colspan="1" rowspan="1">25(26,88%)</td><td align="char" char="." colspan="1" rowspan="1">213(40,19%)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Male</td><td align="center" colspan="1" rowspan="1">6 (37.5%)</td><td align="center" colspan="1" rowspan="1">9 (64.3%)</td><td align="center" colspan="1" rowspan="1">218 (64.7%)</td><td align="char" char="." colspan="1" rowspan="1">145(69,71%)</td><td align="char" char="." colspan="1" rowspan="1">68(73,12%)</td><td align="char" char="." colspan="1" rowspan="1">317(59,81%)</td></tr><tr><td colspan="7" align="left" rowspan="1"><bold>Functionality level (ECOG status), n (%)</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;ECOG 0&#8211;1</td><td align="center" colspan="1" rowspan="1">16 (100%)</td><td align="center" colspan="1" rowspan="1">14 (100%)</td><td align="center" colspan="1" rowspan="1">321 (95.3%)</td><td align="char" char="." colspan="1" rowspan="1">189(90,87%)</td><td align="char" char="." colspan="1" rowspan="1">89(95,70%)</td><td align="char" char="." colspan="1" rowspan="1">428(80,75%)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;ECOG &#8805;2</td><td align="center" colspan="1" rowspan="1">0(0,00%)</td><td align="center" colspan="1" rowspan="1">0(0,00%)</td><td align="center" colspan="1" rowspan="1">16 (4.75%)</td><td align="char" char="." colspan="1" rowspan="1">19(9,13%)</td><td align="char" char="." colspan="1" rowspan="1">4(4,30%)</td><td align="char" char="." colspan="1" rowspan="1">102(19,25%)</td></tr><tr><td colspan="7" align="left" rowspan="1"><bold>Histology, n (%)</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Clear cell</td><td align="center" colspan="1" rowspan="1">4 (25%)</td><td align="center" colspan="1" rowspan="1">11 (78.6%)</td><td align="center" colspan="1" rowspan="1">264 (78.3%)</td><td align="char" char="." colspan="1" rowspan="1">180(86,54%)</td><td align="char" char="." colspan="1" rowspan="1">73(78,49%)</td><td align="char" char="." colspan="1" rowspan="1">348(65,66%)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Non-clear cell</td><td align="center" colspan="1" rowspan="1">0(0,00%)</td><td align="center" colspan="1" rowspan="1">1 (7.1%)</td><td align="center" colspan="1" rowspan="1">27 (8%)</td><td align="char" char="." colspan="1" rowspan="1">10(4,81%)</td><td align="char" char="." colspan="1" rowspan="1">7(7,53%)</td><td align="char" char="." colspan="1" rowspan="1">83(15,66%)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;NOS</td><td align="center" colspan="1" rowspan="1">12 (75.00%)</td><td align="center" colspan="1" rowspan="1">2 (14.3%)</td><td align="center" colspan="1" rowspan="1">46(13.7%)</td><td align="char" char="." colspan="1" rowspan="1">18(8,65%)</td><td align="char" char="." colspan="1" rowspan="1">13(13,98%)</td><td align="char" char="." colspan="1" rowspan="1">99(18,68%)</td></tr><tr><td colspan="7" align="left" rowspan="1"><bold>Metastatic sites, n (%)</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Lung</td><td align="center" colspan="1" rowspan="1">8 (50%)</td><td align="center" colspan="1" rowspan="1">12 (85.7%)</td><td align="center" colspan="1" rowspan="1">225 (66.8%)</td><td align="char" char="." colspan="1" rowspan="1">157(75,48%)</td><td align="char" char="." colspan="1" rowspan="1">64(68,82%)</td><td align="char" char="." colspan="1" rowspan="1">246(46,42%)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Liver</td><td align="center" colspan="1" rowspan="1">4 (25%)</td><td align="center" colspan="1" rowspan="1">3 (21.4%)</td><td align="center" colspan="1" rowspan="1">46 (13.7%)</td><td align="char" char="." colspan="1" rowspan="1">59(28,37%)</td><td align="char" char="." colspan="1" rowspan="1">24(25,81%)</td><td align="char" char="." colspan="1" rowspan="1">126(23,77%)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Bone</td><td align="center" colspan="1" rowspan="1">4 (25%)</td><td align="center" colspan="1" rowspan="1">1 (7.1%)</td><td align="center" colspan="1" rowspan="1">67 (19.9%)</td><td align="char" char="." colspan="1" rowspan="1">47(22,60%)</td><td align="char" char="." colspan="1" rowspan="1">20(21,51%)</td><td align="char" char="." colspan="1" rowspan="1">136(25,66%)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Lymph nodes</td><td align="center" colspan="1" rowspan="1">3 (18.8%)</td><td align="center" colspan="1" rowspan="1">8 (57.1%)</td><td align="center" colspan="1" rowspan="1">121 (35.9%)</td><td align="char" char="." colspan="1" rowspan="1">97(46,63%)</td><td align="char" char="." colspan="1" rowspan="1">40(43,01%)</td><td align="char" char="." colspan="1" rowspan="1">217(40,94%)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Brain</td><td align="center" colspan="1" rowspan="1">1 (6.3%)</td><td align="center" colspan="1" rowspan="1">0(0,00%)</td><td align="center" colspan="1" rowspan="1">2 (0.6%)</td><td align="char" char="." colspan="1" rowspan="1">12(5,77%)</td><td align="char" char="." colspan="1" rowspan="1">3(3,23%)</td><td align="char" char="." colspan="1" rowspan="1">7(1,32%)</td></tr><tr><td colspan="7" align="left" rowspan="1"><bold>Comorbidities, n (%)</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Diabetes</td><td align="center" colspan="1" rowspan="1">4 (25%)</td><td align="center" colspan="1" rowspan="1">2 (14.3%)</td><td align="center" colspan="1" rowspan="1">91 (27%)</td><td align="char" char="." colspan="1" rowspan="1">22(10,58%)</td><td align="char" char="." colspan="1" rowspan="1">17(18,28%)</td><td align="char" char="." colspan="1" rowspan="1">128(24,15%)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;COPD</td><td align="center" colspan="1" rowspan="1">0(0,00%)</td><td align="center" colspan="1" rowspan="1">1 (7.1%)</td><td align="center" colspan="1" rowspan="1">39 (11.6%)</td><td align="char" char="." colspan="1" rowspan="1">23(11,06%)</td><td align="char" char="." colspan="1" rowspan="1">13(13,98%)</td><td align="char" char="." colspan="1" rowspan="1">118(22,26%)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Renal dysfunction</td><td align="center" colspan="1" rowspan="1">1 (6.5%)</td><td align="center" colspan="1" rowspan="1">1 (7.1%)</td><td align="center" colspan="1" rowspan="1">37 (11%)</td><td align="char" char="." colspan="1" rowspan="1">15(7,21%)</td><td align="char" char="." colspan="1" rowspan="1">6(6,45%)</td><td align="char" char="." colspan="1" rowspan="1">53(10,00%)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Cardiac dysfunction</td><td align="center" colspan="1" rowspan="1">3 (18.8%)</td><td align="center" colspan="1" rowspan="1">1 (7.1%)</td><td align="center" colspan="1" rowspan="1">33 (9.8%)</td><td align="char" char="." colspan="1" rowspan="1">6(2,88%)</td><td align="char" char="." colspan="1" rowspan="1">0(0,00%)</td><td align="char" char="." colspan="1" rowspan="1">42(7,92%)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Atrial fibrillation</td><td align="center" colspan="1" rowspan="1">1 (6.3%)</td><td align="center" colspan="1" rowspan="1">0(0,00%)</td><td align="center" colspan="1" rowspan="1">21 (6.2%)</td><td align="char" char="." colspan="1" rowspan="1">4(1,92%)</td><td align="char" char="." colspan="1" rowspan="1">4(4,30%)</td><td align="char" char="." colspan="1" rowspan="1">47(8,87%)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;None</td><td align="center" colspan="1" rowspan="1">8 (50%)</td><td align="center" colspan="1" rowspan="1">7 (50.00%)</td><td align="center" colspan="1" rowspan="1">118 (35%)</td><td align="char" char="." colspan="1" rowspan="1">125(60,10%)</td><td align="char" char="." colspan="1" rowspan="1">40(43,01%)</td><td align="char" char="." colspan="1" rowspan="1">197(37,17%)</td></tr><tr><td colspan="7" align="left" rowspan="1"><bold>Specialist, n (%)</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Oncologist</td><td align="center" colspan="1" rowspan="1">16 (100%)</td><td align="center" colspan="1" rowspan="1">14(100%)</td><td align="center" colspan="1" rowspan="1">305 (90.5%)</td><td align="char" char="." colspan="1" rowspan="1">208(100,00%)</td><td align="char" char="." colspan="1" rowspan="1">92(98,92%)</td><td align="char" char="." colspan="1" rowspan="1">448(84,53%)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Urologist</td><td align="center" colspan="1" rowspan="1">0(0,00%)</td><td align="center" colspan="1" rowspan="1">0(0,00%)</td><td align="center" colspan="1" rowspan="1">32 (9.5%)</td><td align="char" char="." colspan="1" rowspan="1">0(0,00%)</td><td align="char" char="." colspan="1" rowspan="1">1(1,08%)</td><td align="char" char="." colspan="1" rowspan="1">82(15,47%)</td></tr></tbody></table><table-wrap-foot><fn id="tfn0003"><p>Missing data reflects the absence of reported therapy.</p></fn><fn id="tfn0004"><p>COPD, Chronic Obstructive Pulmonary Disease; ECOG, Eastern Cooperative Oncology Group; IO, Immuno-Oncology; NOS, Not other specified; TKI, Tyrosine Kinase Inhibitor.</p></fn></table-wrap-foot></table-wrap></p><p>Of the total patient cohort, <xref rid="t0003" ref-type="table">Table 3</xref> summarizes the distribution of the three main therapies treatments among the 900 patients receiving 1&#8201;L treatment for clear cell mRCC (mccRCC), stratified by IMDC prognostic classification, doctor&#8217;s specialty and year of treatment. In 2022, 151 patients were categorized under the IMDC FP classification. Among these, 92.7% of patients managed by medical oncologists received 1&#8201;L treatment with TKIs, whereas 100% of those managed by urologists were treated with TKIs. Conversely, of the 320 patients classified under IP/PP, 56.7% managed by medical oncologists received TKI therapy, 27.5% were administered anti-PD1-antiCTLA4 therapy, and 13.8% received a combination of anti-PD1 and TKI. Urologists administered TKI therapy to 95.5% of IP/PP patients, with 4.5% receiving anti-PD1-TKI combination therapy. No patients under urological care received anti-PD1-antiCTLA4 therapy. In 2023, 130 patients were classified under the IMDC FP category, with 94.4% of those under medical oncology care receiving 1&#8201;L treatment with TKIs. All six patients under urological care received TKIs. Among the 299 patients classified as IP/PP, 48.4% managed by medical oncologists received TKI therapy, 38.3% were treated with anti-PD1-antiCTLA4 therapy, and 12.1% received a combination of anti-PD1 and TKI. Urologists administered TKI therapy to 76.7% of IP/PP patients, with 23.3% receiving other unspecified therapies and none receiving anti-PD1-antiCTLA4 therapy. It is noteworthy that some patients received IO/TKI combinations during the study period, which are not covered by the national public healthcare system in Spain.<table-wrap position="float" id="t0003" orientation="portrait"><label>Table 3.</label><caption><p>1&#8201;L treatment for patients with mccRCC according to IMDC and doctors&#8217; specialty.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col width="1*" align="left" span="1"/><col width="1*" align="center" span="1"/><col width="1*" align="center" span="1"/><col width="1*" align="center" span="1"/><col width="1*" align="center" span="1"/></colgroup><thead><tr><th align="left" colspan="1" rowspan="1">&#160;</th><th colspan="2" align="center" rowspan="1">Medical Oncology 2022<hr/></th><th colspan="2" align="center" rowspan="1">Medical Oncology 2023<hr/></th></tr><tr><th align="left" colspan="1" rowspan="1">&#160;</th><th align="center" colspan="1" rowspan="1">IMDC FP</th><th align="center" colspan="1" rowspan="1">IMDC IP/PP</th><th align="center" colspan="1" rowspan="1">IMDC FP</th><th align="center" colspan="1" rowspan="1">IMDC IP/PP</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">N</td><td align="center" colspan="1" rowspan="1">137</td><td align="center" colspan="1" rowspan="1">298</td><td align="center" colspan="1" rowspan="1">124</td><td align="center" colspan="1" rowspan="1">256</td></tr><tr><td align="left" colspan="1" rowspan="1">% TKI</td><td align="center" colspan="1" rowspan="1">92,7%</td><td align="center" colspan="1" rowspan="1">56,7%</td><td align="center" colspan="1" rowspan="1">94,4%</td><td align="center" colspan="1" rowspan="1">48,4%</td></tr><tr><td align="left" colspan="1" rowspan="1">% antiPD1-antiCTLA4</td><td align="center" colspan="1" rowspan="1">2,2%</td><td align="center" colspan="1" rowspan="1">27,5%</td><td align="center" colspan="1" rowspan="1">0,8%</td><td align="center" colspan="1" rowspan="1">38,3%</td></tr><tr><td align="left" colspan="1" rowspan="1">% antiPD1 - TKI<hr/></td><td align="center" colspan="1" rowspan="1">5,1%<hr/></td><td align="center" colspan="1" rowspan="1">13,8%<hr/></td><td align="center" colspan="1" rowspan="1">3,2%<hr/></td><td align="center" colspan="1" rowspan="1">12,1%<hr/></td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td colspan="2" align="center" rowspan="1">Urology 2022<hr/></td><td colspan="2" align="center" rowspan="1">Urology 2023<hr/></td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;<hr/></td><td align="center" colspan="1" rowspan="1">IMDC FP<hr/></td><td align="center" colspan="1" rowspan="1">IMDC IP/PP<hr/></td><td align="center" colspan="1" rowspan="1">IMDC FP<hr/></td><td align="center" colspan="1" rowspan="1">IMDC IP/PP<hr/></td></tr><tr><td align="left" colspan="1" rowspan="1">N</td><td align="center" colspan="1" rowspan="1">14</td><td align="center" colspan="1" rowspan="1">22</td><td align="center" colspan="1" rowspan="1">6</td><td align="center" colspan="1" rowspan="1">43</td></tr><tr><td align="left" colspan="1" rowspan="1">% TKI</td><td align="center" colspan="1" rowspan="1">100%</td><td align="center" colspan="1" rowspan="1">95,5%</td><td align="center" colspan="1" rowspan="1">100%</td><td align="center" colspan="1" rowspan="1">76,7%</td></tr><tr><td align="left" colspan="1" rowspan="1">% antiPD1-antiCTLA4</td><td align="center" colspan="1" rowspan="1">&#8211;</td><td align="center" colspan="1" rowspan="1">&#8211;</td><td align="center" colspan="1" rowspan="1">&#8211;</td><td align="center" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" colspan="1" rowspan="1">% antiPD1 - TKI</td><td align="center" colspan="1" rowspan="1">&#8211;</td><td align="center" colspan="1" rowspan="1">4,5%</td><td align="center" colspan="1" rowspan="1">&#8211;</td><td align="center" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" colspan="1" rowspan="1">Other therapies</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">23.3%</td></tr></tbody></table><table-wrap-foot><fn id="tfn0005"><p>Missing data reflects the absence of reported therapy.</p></fn><fn id="tfn0006"><p>CTLA4, cytotoxic T- lymphocyte- associated protein 4; FP, favorable prognosis; IMDC, International Metastatic renal cell carcinoma Database Consortium; IP, intermediate prognosis; mccRCC, metastatic clear cell Renal Cell Carcinoma; PD1, programmed cell death&#8211;1 protein; PP, poor prognosis; TKI, Tyrosine Kinase Inhibitor.</p></fn></table-wrap-foot></table-wrap></p><p>The management of RCC patients&#8217; treatment in the 2&#8201;L and beyond is outlined in <xref rid="t0004" ref-type="table">Table 4</xref>. A total of 190 patients were reported in 2022 and 173 in 2023, with similar treatment patterns across both years. In 2022, most patients received TKI monotherapy, primarily cabozantinib (39.5%), followed by sunitinib (6.3%), pazopanib (6.3%), and other TKIs. Immunotherapy was administered to 45.2% of patients, mainly as nivolumab monotherapy (44.7%), with a small proportion receiving nivolumab plus ipilimumab (0.5%). In 2023, 56.0% of patients were treated with TKI monotherapy, again led by cabozantinib (38.2%), followed by sunitinib (11.0%), pazopanib (5.8%), and other TKIs. Immunotherapy use remained consistent, with 42.2% of patients receiving nivolumab monotherapy and 1.2% receiving nivolumab plus ipilimumab. Notably, treatment patterns differed between specialties. In 2022, oncologists favored cabozantinib (42.2%) and nivolumab monotherapy (49.1%), while urologists used pazopanib (31.0%) and sunitinib (20.7%) more frequently. In 2023, oncologists continued to favor cabozantinib (40.9%) and nivolumab monotherapy (45.9%), while urologists showed a preference for pazopanib (57.1%) and sunitinib (35.7%). Among urologists, pazopanib use increased significantly in 2023, compared to 31.0% in 2022, while nivolumab monotherapy was not used by urologists in 2023.<table-wrap position="float" id="t0004" orientation="portrait"><label>Table 4.</label><caption><p>Treatment management of RCC patients in 2&#8201;L and beyond by specialty.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col width="1*" align="left" span="1"/><col width="1*" align="center" span="1"/><col width="1*" align="center" span="1"/><col width="1*" align="center" span="1"/><col width="1*" align="center" span="1"/><col width="1*" align="center" span="1"/><col width="1*" align="center" span="1"/></colgroup><thead><tr><th align="left" colspan="1" rowspan="1">&#160;</th><th colspan="3" align="center" rowspan="1">Patients in 2&#8201;L+ reported in 2022<hr/></th><th colspan="3" align="center" rowspan="1">Patients in 2&#8201;L+ reported in 2023<hr/></th></tr><tr><th align="left" colspan="1" rowspan="1">Treatments, n(%)</th><th align="center" colspan="1" rowspan="1">Oncologist<break/>N&#8201;=&#8201;161</th><th align="center" colspan="1" rowspan="1">Urologist<break/>N&#8201;=&#8201;29</th><th align="center" colspan="1" rowspan="1">Oncologists&#8201;+&#8201;Urologists<break/>N&#8201;=&#8201;190</th><th align="center" colspan="1" rowspan="1">Oncologists<break/>N&#8201;=&#8201;159</th><th align="center" colspan="1" rowspan="1">Urologist<break/>N&#8201;=&#8201;14</th><th align="center" colspan="1" rowspan="1">Oncologists&#8201;+&#8201;Urologists<break/>N&#8201;=&#8201;173</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Cabozantinib monotherapy</td><td align="center" colspan="1" rowspan="1">68(42,24%)</td><td align="center" colspan="1" rowspan="1">7(24,14%)</td><td align="center" colspan="1" rowspan="1">75(39,47%)</td><td align="center" colspan="1" rowspan="1">65(40,88%)</td><td align="center" colspan="1" rowspan="1">1(7,14%)</td><td align="center" colspan="1" rowspan="1">66(38,15%)</td></tr><tr><td align="left" colspan="1" rowspan="1">Nivolumab&#8201;+&#8201;Ipilimumab</td><td align="center" colspan="1" rowspan="1">1(0,62%)</td><td align="center" colspan="1" rowspan="1">0(0,00%)</td><td align="center" colspan="1" rowspan="1">1(0,53%)</td><td align="center" colspan="1" rowspan="1">2(1,26%)</td><td align="center" colspan="1" rowspan="1">0(0,00%)</td><td align="center" colspan="1" rowspan="1">2(1,16%)</td></tr><tr><td align="left" colspan="1" rowspan="1">Nivolumab monotherapy</td><td align="center" colspan="1" rowspan="1">79(49,07%)</td><td align="center" colspan="1" rowspan="1">6(20,69%)</td><td align="center" colspan="1" rowspan="1">85(44,74%)</td><td align="center" colspan="1" rowspan="1">73(45,91%)</td><td align="center" colspan="1" rowspan="1">0(0,00%)</td><td align="center" colspan="1" rowspan="1">73(42,20%)</td></tr><tr><td align="left" colspan="1" rowspan="1">Other Tyrosine Kinase Inhibitors monotherapy</td><td align="center" colspan="1" rowspan="1">4(2,48%)</td><td align="center" colspan="1" rowspan="1">1(3,45%)</td><td align="center" colspan="1" rowspan="1">5(2,63%)</td><td align="center" colspan="1" rowspan="1">1(0,63%)</td><td align="center" colspan="1" rowspan="1">0(0,00%)</td><td align="center" colspan="1" rowspan="1">1(0,58%)</td></tr><tr><td align="left" colspan="1" rowspan="1">Pazopanib monotherapy</td><td align="center" colspan="1" rowspan="1">3(1,86%)</td><td align="center" colspan="1" rowspan="1">9(31,03%)</td><td align="center" colspan="1" rowspan="1">12(6,32%)</td><td align="center" colspan="1" rowspan="1">2(1,26%)</td><td align="center" colspan="1" rowspan="1">8(57,14%)</td><td align="center" colspan="1" rowspan="1">10(5,78%)</td></tr><tr><td align="left" colspan="1" rowspan="1">Pembrolizumab&#8201;+&#8201;Axitinib</td><td align="center" colspan="1" rowspan="1">0(0,00%)</td><td align="center" colspan="1" rowspan="1">0(0,00%)</td><td align="center" colspan="1" rowspan="1">0(0,00%)</td><td align="center" colspan="1" rowspan="1">1(0,63%)</td><td align="center" colspan="1" rowspan="1">0(0,00%)</td><td align="center" colspan="1" rowspan="1">1(0,58%)</td></tr><tr><td align="left" colspan="1" rowspan="1">Sunitinib monotherapy</td><td align="center" colspan="1" rowspan="1">6(3,73%)</td><td align="center" colspan="1" rowspan="1">6(20,69%)</td><td align="center" colspan="1" rowspan="1">12(6,32%)</td><td align="center" colspan="1" rowspan="1">14(8,81%)</td><td align="center" colspan="1" rowspan="1">5(35,71%)</td><td align="center" colspan="1" rowspan="1">19(10,98%)</td></tr><tr><td align="left" colspan="1" rowspan="1">Tivozanib monotherapy</td><td align="center" colspan="1" rowspan="1">0(0,00%)</td><td align="center" colspan="1" rowspan="1">0(0,00%)</td><td align="center" colspan="1" rowspan="1">0(0,00%)</td><td align="center" colspan="1" rowspan="1">1(0,63%)</td><td align="center" colspan="1" rowspan="1">0(0,00%)</td><td align="center" colspan="1" rowspan="1">1(0,58%)</td></tr></tbody></table><table-wrap-foot><fn id="tfn0007"><p>Missing data reflects the absence of reported therapy.</p></fn><fn id="tfn0008"><p>2&#8201;L, Second line; TKI, Tyrosine Kinase Inhibitor.</p></fn></table-wrap-foot></table-wrap></p><p>Additionally, the study explored the most common sequences of 1&#8201;L and 2&#8201;L treatments. In 2022, the most prevalent treatment sequence started with a 1&#8201;L treatment using a TKI monotherapy, specifically sunitinib (46.5%) or pazopanib (34.6%), as seen in <xref rid="f0001" ref-type="fig">Figure 1</xref>. When the treatment advanced to the 2&#8201;L, the regimen usually changed to nivolumab monotherapy, which was applied in 50.3% of the 2&#8201;L cases. The other most frequent sequence after progression from 1&#8201;L was to a 2&#8201;L cabozantinib, monotherapy what happened in 35.8% of instances. In <xref rid="f0002" ref-type="fig">Figure 2</xref> that outlines the treatment progression from 1&#8201;L to 2&#8201;L in 2023, we found a slight modification of the pattern with an increase in the number of patients (22.1%) receiving a combination of nivolumab and ipilimumab in first line. Upon progression to the 2&#8201;L, these patients typically switched to cabozantinib monotherapy.
<fig position="float" id="f0001" fig-type="figure" orientation="portrait"><label>Figure 1.</label><caption><p>2022 treatment flow for patients on 2&#8201;L.</p></caption><alternatives><graphic content-type="color" specific-use="web-only" position="float" orientation="portrait" xlink:href="IFON_A_2542030_F0001_OC.jpg"/><graphic content-type="black-white" specific-use="print-only" position="float" orientation="portrait" xlink:href="IFON_A_2542030_F0001_PB.jpg"/></alternatives><attrib>1&#8201;L, First line; 2&#8201;L, Second line; Axi, Axitinib; Cabo, Cabozantinib; Ipi, Ipilimumab; Lenva, Lenvatinib; mTOR, mechanistic Target of Rapamycin; Nivo, Nivolumab; Pazo, Pazopanib; Pembro, Pembrolizumab; Suni, Sunitinib; Tivo, Tivozanib; TKI, Tyrosine Kinase Inhibitor.</attrib></fig>
<fig position="float" id="f0002" fig-type="figure" orientation="portrait"><label>Figure 2.</label><caption><p>2023 treatment flow for patients on 2&#8201;L.</p></caption><alternatives><graphic content-type="color" specific-use="web-only" position="float" orientation="portrait" xlink:href="IFON_A_2542030_F0002_OC.jpg"/><graphic content-type="black-white" specific-use="print-only" position="float" orientation="portrait" xlink:href="IFON_A_2542030_F0002_PB.jpg"/></alternatives><attrib>1&#8201;L, First line; 2&#8201;L, Second line; Axi, Axitinib; Cabo, Cabozantinib; Ipi, Ipilimumab; Lenva, Lenvatinib; mTOR, mechanistic Target of Rapamycin Nivo, Nivolumab; Pazo, Pazopanib; Pembro, Pembrolizumab; Suni, Sunitinib; Tivo, Tivozanib; TKI, Tyrosine Kinase Inhibitor.</attrib></fig></p></sec><sec disp-level="1" id="s0004"><label>4.</label><title>Discussion</title><p>The therapeutic landscape of mRCC has evolved substantially over the past decade, driven by advances in molecular imaging [<xref rid="cit0011" ref-type="bibr">11</xref>], surgical techniques [<xref rid="cit0011" ref-type="bibr">11</xref>], and personalized medicine [<xref rid="cit0012" ref-type="bibr">12</xref>], including TKI, IO and their combinations [<xref rid="cit0013" ref-type="bibr">13&#8211;16</xref>]. While our data indicate a slower-than-expected incorporation of these therapies into routine clinical practice, these therapies have significantly improved patient outcomes, as evidenced by the results of phase III controlled clinical trials. However, real-world data on mRCC patients in this new treatment paradigm is lacking. This cross-sectional study was designed to evaluate real-world treatment patterns for mRCC, stratified by IMDC prognostic classification and medical specialty. The demographic and clinical characteristics of our cohort were consistent with those reported in both real-world studies and pivotal clinical trials [<xref rid="cit0017" ref-type="bibr">17&#8211;19</xref>], supporting the external validity of our findings.</p><p>Current guidelines still recommend the use of TKI for selected patients of FP. On the other hand, the combination IO/IO improve response rate, progression-free survival (PFS) and overall survival (OS) in the IP/PP subgroups compared to sunitinib. Clinical trials of I/O-TKI combinations where focused on the overall mRCC population including FP/IP/PP patients, showing a significantly better Objective Response Rate (ORR), PFS and OS over TKI monotherapy [<xref rid="cit0014" ref-type="bibr">14&#8211;16</xref>]. However, these Phase III clinical trials show a more pronounced benefit in patients with intermediate or poor IMDC risk compared with those with favorable risk [<xref rid="cit0020" ref-type="bibr">20&#8211;22</xref>], where no differences in OS were found in the subgroup analysis of any of them. Although patients with a favorable prognosis could also benefit from TKI monotherapy [<xref rid="cit0023" ref-type="bibr">23</xref>], a recent 2024 meta-analysis by Bolek et al., patients in the IMDC FP receiving IO/TKI regimens had a 33% reduction in the risk of disease progression (Hazard Ratio [HR], 0.67 [95% CI, 0.55&#8211;0.82]; P&#8201;&lt;&#8201;.001) and a higher ORR (odds ratio [OR], 0.40 [95% CI, 0.28&#8211;0.57]; P&#8201;&lt;&#8201;.001), but showed similar OS compared with sunitinib; which suggests that while TKI monotherapy could still be a viable option for patients with a favorable prognosis, IO/TKI combinations can improve disease control in these patients [<xref rid="cit0024" ref-type="bibr">24</xref>].</p><p>Regarding the utilization of IO combinations, the Checkmate-214 phase III trial compared the efficacy of a combination therapy of ipilimumab and nivolumab against sunitinib, a standard TKI therapy. The results were compelling; the combination therapy not only achieved a higher ORR but also showed significant improvements in OS and PFS. After an extensive follow-up period of 8&#8201;years, the median OS for the combination therapy was recorded at 46.7&#8201;months compared to 26.0&#8201;months for sunitinib (HR: 0.69). The ORR also favored the combination therapy at 42% versus 27% for sunitinib [<xref rid="cit0025" ref-type="bibr">25</xref>].</p><p>Several other studies have further validated the efficacy of IO/TKI combinations over sunitinib in the mRCC patient population. The Keynote 426 trial investigated the combination of pembrolizumab and axitinib versus sunitinib alone. The trial reported an ORR of 59% for the combination therapy compared to 36% for sunitinib. Additionally, the median PFS was significantly longer in the combination group at 15.1&#8201;months, as opposed to 11.1&#8201;months for those receiving sunitinib alone (HR: 0.69). The median OS also showed a marked improvement, with the combination therapy not reaching the median compared to 35.7&#8201;months for sunitinib (HR: 0.53) [<xref rid="cit0022" ref-type="bibr">22</xref>]. Similarly, the CheckMate 9ER trial, which compared nivolumab plus cabozantinib against sunitinib, demonstrated an ORR of 56% for the combination therapy versus 27% for sunitinib. The median PFS was notably longer at 16.6&#8201;months for the combination therapy, compared to 8.3&#8201;months for sunitinib (HR: 0.51) [<xref rid="cit0021" ref-type="bibr">21</xref>]. Lastly, the CLEAR trial, which evaluated the combination of lenvatinib and pembrolizumab against sunitinib, showed an even more dramatic difference in ORR&#8212;71% for the combination therapy versus 36% for sunitinib. The median PFS for the combination therapy was a substantial 24&#8201;months, compared to just 9&#8201;months for those on sunitinib (HR: 0.39) [<xref rid="cit0026" ref-type="bibr">26</xref>].</p><p>Despite these findings, our study shows that TKI monotherapy remained the predominant 1&#8201;L RCC treatment across all risk groups in 2022 and 2023. Among 1&#8201;L patients with mccRCC, 281&#160;had FP and 619&#160;had IP/PP, of which most patients received 1&#8201;L treatment with TKI. Among TKIs, sunitinib remains the most widely prescribed, which is coherent with other studies, despite the COMPARZ study showing that pazopanib had similar efficacy to sunitinib but possibly worse tolerability for sunitinib. One possible explanation is that sunitinib was the first TKI approved by the European Medicines Agency in 2006, which may have contributed to a certain inertia in clinical practice. Additionally, the availability of generic versions of sunitinib may further support its continued use. Although a small proportion of patients were managed by urologist, in most of them the decision was taken by medical oncologists. These results underscore that a significant proportion of patients may be receiving suboptimal treatment, as IO/TKI combinations have been shown to be superior to TKI monotherapy for this patient population, particularly in the IP/PP IMDC subgroup.</p><p>It is important to contextualize these findings within the Spanish healthcare system. Although the EMA approved nivolumab plus ipilimumab for IMDC IP/PP patients in 2019, national reimbursement in Spain was only granted in October 2021. This delay, coupled with the lingering effects of the COVID-19 pandemic, may have contributed to the continued reliance on TKIs during the study period. Furthermore, IO/TKI combinations, despite EMA approval, are not yet reimbursed in Spain, which likely limits their adoption in clinical practice. It should be remarked that at least in patients with IMDC IP/PP, TKI monotherapy should be considered suboptimal. However, the two most relevant 2&#8201;L therapies which have demonstrated to improve OS after 1&#8201;L with TKIs, were widely available and used in this series.</p><p>Despite the predominance of TKI monotherapy, our data indicate a gradual but notable shift toward combination therapies, particularly in patients with intermediate and poor-risk profiles. Among mccRCC patients managed by oncologists and receiving 1&#8201;L treatment, the adoption of IO combinations (antiPD1-antiCTLA4), increased by 10.8% from 2022 to 2023 (from 27.5% in 2022 to 38.3% in 2023). This trend aligns with the latest clinical guidelines [<xref rid="cit0014" ref-type="bibr">14&#8211;16</xref>]. Although there is still a considerable number of patients that are potentially untreated during the study period as around half of the IP/PP patients included in the study that are managed by oncologists were administered TKI monotherapy&#8211;56.7% in 2022 and 48.4% in 2023.</p><p>Our study showcases that the majority of patients are managed by oncologists, although we observe a small proportion of patients managed by urologists. This specialists appear to favor TKI for all RCC risk groups, which is significant as it suggests they may not be adhering to the most recent clinical guidelines.</p><p>This study has several limitations inherent to its cross-sectional design, which captures treatment patterns at a single point in time and does not allow for longitudinal assessment of treatment sequences or changes in clinical decision-making over time. Additionally, although IO/IO combination was nationally reimbursed in Spain during the study period, its underutilization may also reflect local restrictions imposed by regional health authorities or even hospital-level access limitations. These contextual factors should be considered when interpreting the observed treatment patterns and their alignment with current clinical guidelines.</p></sec><sec disp-level="1" id="s0005"><label>5.</label><title>Conclusion</title><p>Despite significant advancements in the therapeutic landscape for mRCC, our analysis reveals a persistent trend where TKI monotherapy remains the predominant initial treatment across all risk categories. Although IO/IO combinations are authorized and reimbursed in Spain, their integration into standard clinical practice has been slower than anticipated. Furthermore, while clinical guidelines and research consistently demonstrate the superior efficacy of IO/TKI combinations in enhancing both overall survival and progression-free survival, particularly within IP/PP subgroups, the adoption of IO/TKI combination therapies remains suboptimal. This could be attributed to the lack of reimbursement of these combinations from the national healthcare system.</p><p>In the specific context of 1&#8201;L mccRCC patients, our data reveals that nearly half of the IP/PP patients managed by oncologists continued to receive TKI monotherapy&#8212;56.7% in 2022 and 48.4% in 2023. This suggests a potential undertreatment of this subgroup, specifically considering that clinical guidelines recommend IO/IO and IO/TKI combinations due to their superior clinical outcomes. The continued reliance on TKI monotherapy, despite the availability of more effective combination regimens, underscores a significant discrepancy between clinical evidence and routine clinical practice. This discrepancy could potentially compromise patient outcomes in the management of mccRCC. Bridging this gap is imperative to ensure that clinical practice aligns with the most robust and current evidence, thereby enhancing the therapeutic management of mccRCC patients.</p><p>The findings of our study underscore the need to bridge this gap between research and clinical practice. This alignment is crucial for enhancing the therapeutic management of mccRCC patients and ensuring that they receive the most effective treatments available. Moreover, our study highlights the evolving nature of RCC treatment, characterized by a slow but steady increase in the adoption of combination therapies, particularly for patients with higher-risk profiles. This trend is likely to continue as more data become available, further supporting the efficacy and safety of these newer treatment regimens.</p></sec></body><back><sec disp-level="1" id="s0006"><title>Article highlights</title><p>
<list list-type="bullet" id="list_0001"><list-item><p>The approval of of immune checkpoint inhibitors (IO), both alone and in combination with tyrosine kinase inhibitors (TKIs), has significantly transformed first line (1&#8201;L) treatment paradigm for metastatic renal cell carcinoma (mRCC), improving key clinical outcomes. However, their adoption in clinical practice varies across countries.</p></list-item><list-item><p>In light of evolving treatment guidelines, this study aimed to generate real-world evidence on the implementation of these therapies by analyzing current treatment patterns for mRCC patients in routine clinical practice in Spain.</p></list-item><list-item><p>A cross-sectional study was conducted using data from the Oncology Dynamics&#8482; database to describe treatment patterns in mRCC patients. Patients were stratified by International Metastatic RCC Database Consortium (IMDC) prognostic groups (favorable vs. intermediate/poor), histology (clear cell vs. non-clear cell), demographics, clinical characteristics, and the treating specialist (oncologist or urologist).</p></list-item><list-item><p>The study included 1,587 mRCC patients, predominantly managed by oncologists.</p></list-item><list-item><p>Among these, 1,224 were 1&#8201;L patients, with 73.5% exhibiting clear cell renal cell carcinoma (ccRCC) histology. About 30.2% of the 1&#8201;L cohort had a favorable prognosis, 37% had an intermediate prognosis, and 32.8% were classified with a poor prognosis.</p></list-item><list-item><p>At the time of data collection, TKI monotherapy was the prevailing treatment across all prognostic groups for mccRCC patients. Specifically, oncologists administered TKI monotherapy to 92.7% of favorable prognosis (FP) patients in 2022 and 94.4% in 2023. Conversely, intermediate and poor prognosis (IP/PP) patients managed by oncologists received TKI monotherapy at rates of 56.7% in 2022 and 48.4% in 2023.</p></list-item><list-item><p>Despite prevailing guidelines advocating for the use of IO/IO in IP/PP patients, the adoption of these combinations remained low, with only 27.5% in 2022 and 38.3% in 2023 receiving such treatment from oncologists. The low adoption rate of IO/TKI combinations, despite their approval in Spain, may be attributed to the lack of reimbursement during the study period. Urologists consistently preferred TKI monotherapy across all prognostic mccRCC subgroups, with minimal use of combination therapies.</p></list-item><list-item><p>In 2&#8201;L, cabozantinib and nivolumab monotherapy were most common. In 2023, IO/IO use increased in 1&#8201;L (22.1%), with patients transitioning to cabozantinib in second line (2&#8201;L).</p></list-item><list-item><p>Regarding treatment sequences, most patients began with TKI monotherapy (sunitinib or pazopanib) and transitioned to nivolumab or cabozantinib in 2&#8201;L. In 2023, there was a slight increase in IO/IO use in 1&#8201;L, followed by cabozantinib in 2&#8201;L.</p></list-item><list-item><p>Overall, the study reveals a strong preference for TKI monotherapy in Spain, even among IP/PP mccRCC patients, highlighting a gap between clinical guidelines and real-world practice.</p></list-item></list></p></sec><sec disp-level="1" id="s0007"><title>Author contributions</title><p>Jos&#233; Angel Arranz: Conceptualization, Methodology, Writing &#8211; Review and Editing</p><p>Cristina Mart&#237;nez: Data curation, Formal analysis</p><p>Luc&#237;a Gallego: Original draft preparation, Writing &#8211; Review and Editing</p><p>Ana Heredero: Data curation, Formal analysis</p><p>Pablo Rebollo: Original draft preparation, Methodology, Writing &#8211; Review and Editing</p><p>Laura Fern&#225;ndez: Conceptualization, Methodology, Writing &#8211; Review and Editing</p><p>Elvira Estella: Conceptualization, Methodology</p><p>David Vilanova: Conceptualization, Methodology, Writing &#8211; Review and Editing</p><p>Virginia Palomar: Conceptualization, Methodology</p></sec><sec sec-type="COI-statement" disp-level="1" id="s0008"><title>Disclosure statement</title><p>Jos&#233; Angel Arranz received honoraria for consulting or advisory role from Pfizer, Astellas, MSD, Bristol-Myers Squibb, Merck, Astra Zeneca, Bayer, Ipsen, and Recordati. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.</p><p>Medical writing support was provided by IQVIA Information and was funded by BMS.</p></sec><sec disp-level="1" id="s0009"><title>Reviewer disclosures</title><p>Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.</p></sec><sec disp-level="1" id="s0010"><title>Ethical declaration</title><p>The authors state that they have obtained appropriate institutional review board approval (Comit&#233; &#201;tico de Investigaci&#243;n con medicamentos del Hospital Cl&#237;nic de Barcelona, HCB/2024/0398)</p></sec><ref-list><title>References</title><p>
<bold>Papers of special note have been highlighted as either of interest (&#8226;) or of considerable interest (&#8226;&#8226;) to readers.</bold>
</p><ref id="cit0001"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Scelo</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Larose</surname><given-names>TL.</given-names></string-name></person-group><article-title>Epidemiology and risk factors for kidney cancer</article-title>. <source>J Clin Oncol</source>. <year>2018</year>;<volume>36</volume>(<issue>36</issue>):<fpage>3574</fpage>&#8211;<lpage>3581</lpage>. doi: <pub-id pub-id-type="doi">10.1200/JCO.2018.79.1905</pub-id><pub-id pub-id-type="pmcid">PMC6299342</pub-id><pub-id pub-id-type="pmid">30372394</pub-id></mixed-citation></ref><ref id="cit0002"><label>2.</label><mixed-citation publication-type="report"><person-group person-group-type="author"><collab>Sociedad Espa&#241;ola de Oncolog&#237;a M&#233;dica (SEOM)</collab></person-group>. <article-title>Las cifras del c&#225;ncer en Espa&#241;a</article-title>. <year>2024</year>.</mixed-citation></ref><ref id="cit0003"><label>3.</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>Kidney Cancer</collab></person-group>. <year>2022</year> [<date-in-citation>cited 2024</date-in-citation>]. <comment>Available from:</comment><ext-link xlink:href="https://www.cancer.net/cancer-types/kidney-cancer" ext-link-type="uri">https://www.cancer.net/cancer-types/kidney-cancer</ext-link></mixed-citation></ref><ref id="cit0004"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Shuch</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Amin</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Armstrong</surname><given-names>AJ</given-names></string-name>, et al</person-group>. <article-title>Understanding pathologic variants of renal cell carcinoma: distilling therapeutic opportunities from biologic complexity</article-title>. <source>Eur Urol</source>. <year>2015</year>;<volume>67</volume>(<issue>1</issue>):<fpage>85</fpage>&#8211;<lpage>97</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.eururo.2014.04.029</pub-id><pub-id pub-id-type="pmid">24857407</pub-id></mixed-citation></ref><ref id="cit0005"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Longo</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Capece</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Celentano</surname><given-names>G</given-names></string-name>, et al</person-group>. <article-title>Clinical and pathological characteristics of metastatic renal cell carcinoma patients needing a second-line therapy: a systematic review</article-title>. <source>Cancers (Basel)</source>. <year>2020</year>;<volume>12</volume>(<issue>12</issue>):<fpage>3634</fpage>. doi: <pub-id pub-id-type="doi">10.3390/cancers12123634</pub-id><pub-id pub-id-type="pmid">33291600</pub-id><pub-id pub-id-type="pmcid">PMC7761871</pub-id></mixed-citation></ref><ref id="cit0006"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Guida</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Le Teuff</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Alves</surname><given-names>C</given-names></string-name>, et al</person-group>. <article-title>Identification of international metastatic renal cell carcinoma database consortium (IMDC) intermediate-risk subgroups in patients with metastatic clear-cell renal cell carcinoma</article-title>. <source>Oncotarget</source>. <year>2020</year>;<volume>11</volume>(<issue>49</issue>):<fpage>4582</fpage>&#8211;<lpage>4592</lpage>. doi: <pub-id pub-id-type="doi">10.18632/oncotarget.27762</pub-id><pub-id pub-id-type="pmid">33346231</pub-id><pub-id pub-id-type="pmcid">PMC7733622</pub-id></mixed-citation></ref><ref id="cit0007"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mantia</surname><given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>McDermott</surname><given-names>DF</given-names></string-name></person-group>. <article-title>Vascular endothelial growth factor and programmed death-1 pathway inhibitors in renal cell carcinoma</article-title>. <source>Cancer</source>. <year>2019</year>;<volume>125</volume>(<issue>23</issue>):<fpage>4148</fpage>&#8211;<lpage>4157</lpage>. doi: <pub-id pub-id-type="doi">10.1002/cncr.32361</pub-id><pub-id pub-id-type="pmid">31532565</pub-id><pub-id pub-id-type="pmcid">PMC6856361</pub-id></mixed-citation></ref><ref id="cit0008"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tannir</surname><given-names>NM</given-names></string-name>, <string-name name-style="western"><surname>Escudier</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>McDermott</surname><given-names>DF</given-names></string-name>, et al</person-group>. <article-title>Nivolumab plus ipilimumab (NIVO+IPI) vs sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC): long-term follow-up data from the phase 3 CheckMate 214 trial</article-title>. <source>J Clin Oncol</source>. <year>2024</year>;<volume>42</volume>(<issue>4_suppl</issue>):<fpage>363</fpage>&#8211;<lpage>363</lpage>. doi: <pub-id pub-id-type="doi">10.1200/JCO.2024.42.4_suppl.363</pub-id></mixed-citation><note><p>
<bold>&#8226;&#8226; This is a landmark phase III clinical trial that has reshaped the standard of care for patients with advanced renal cell carcinoma (aRCC), particularly those with intermediate or poor prognosis. The study demonstrated the long-term efficacy and safety of the combination of nivolumab (a PD-1 inhibitor) and ipilimumab (a CTLA-4 inhibitor) compared to sunitinib, a tyrosine kinase inhibitor (TKI). Its findings led to updates in major international guidelines (e.g. ESMO, NCCN), which now recommend the IO/IO combination (nivolumab + ipilimumab) as a first-line treatment in this patient population. This trial also helped establish immune checkpoint inhibitor combinations as a viable and often preferred alternative to TKI monotherapy or IO/TKI combinations.</bold>
</p></note></ref><ref id="cit0009"><label>9.</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>Agencia Espa&#241;ola del Medicamento (AEMPS)</collab></person-group>. <article-title>Ficha t&#233;cnica Opdivo</article-title>. <year>2024</year>. <comment>Available from:</comment><ext-link xlink:href="https://cima.aemps.es/cima/dochtml/ft/1151014002/FT_1151014002.html" ext-link-type="uri">https://cima.aemps.es/cima/dochtml/ft/1151014002/FT_1151014002.html</ext-link></mixed-citation><note><p>
<bold>&#8226;&#8226; This is the official summary of product characteristics for Opdivo (nivolumab) published by the Spanish Agency of Medicines and Medical Devices (AEMPS). It confirms the regulatory approval and reimbursement status of nivolumab in Spain, which is essential for its clinical implementation in the national healthcare system. This document ensures that the treatment is accessible to patients and endorsed by local regulatory authorities, supporting its use in real-world clinical practice.</bold>
</p></note></ref><ref id="cit0010"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bourlon</surname><given-names>MT</given-names></string-name>, <string-name name-style="western"><surname>Escudier</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Burotto</surname><given-names>M</given-names></string-name>, et al</person-group>. <article-title>Nivolumab plus cabozantinib (N+C) vs sunitinib (S) for previously untreated advanced renal cell carcinoma (aRCC): results from 55-month follow-up of the CheckMate 9ER trial</article-title>. <source>J Clin Oncol</source>. <year>2024</year>;<volume>42</volume>(<issue>4_suppl</issue>):<fpage>362</fpage>&#8211;<lpage>362</lpage>. doi: <pub-id pub-id-type="doi">10.1200/JCO.2024.42.4_suppl.362</pub-id></mixed-citation></ref><ref id="cit0011"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tataru</surname><given-names>OS</given-names></string-name>, <string-name name-style="western"><surname>Marchioni</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Crocetto</surname><given-names>F</given-names></string-name>, et al</person-group>. <article-title>Molecular imaging diagnosis of renal cancer using (99m)Tc-sestamibi SPECT/CT and girentuximab PET-CT-current evidence and future development of novel techniques</article-title>. <source>Diagnostics (Basel)</source>. <year>2023</year>;<volume>13</volume>(<issue>4</issue>):<fpage>593</fpage>. doi: <pub-id pub-id-type="doi">10.3390/diagnostics13040593</pub-id><pub-id pub-id-type="pmid">36832081</pub-id><pub-id pub-id-type="pmcid">PMC9954934</pub-id></mixed-citation></ref><ref id="cit0012"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Crocetto</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Falcone</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Mirto</surname><given-names>BF</given-names></string-name>, et al</person-group>. <article-title>Unlocking precision medicine: liquid biopsy advancements in renal cancer detection and monitoring</article-title>. <source>Int J Mol Sci</source>. <year>2024</year>;<volume>25</volume>(<issue>7</issue>):<fpage>3867</fpage>. doi: <pub-id pub-id-type="doi">10.3390/ijms25073867</pub-id><pub-id pub-id-type="pmid">38612677</pub-id><pub-id pub-id-type="pmcid">PMC11011885</pub-id></mixed-citation></ref><ref id="cit0013"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>de Velasco</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Bex</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Albiges</surname><given-names>L</given-names></string-name>, et al</person-group>. <article-title>Sequencing and combination of systemic therapy in metastatic renal cell carcinoma</article-title>. <source>Eur Urol Oncol</source>. <year>2019</year>;<volume>2</volume>(<issue>5</issue>):<fpage>505</fpage>&#8211;<lpage>514</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.euo.2019.06.022</pub-id><pub-id pub-id-type="pmid">31377308</pub-id></mixed-citation><note><p>
<bold>&#8226; This publication provides a comprehensive review of the optimal sequencing and combination of systemic therapies in mRCC. It is relevant because it helps clinicians understand how to strategically integrate different treatment modalities (IO, TKI, or combinations) over the course of the disease, especially in light of evolving evidence and new approvals. It supports personalized treatment planning based on patient characteristics and prior therapies.</bold>
</p></note></ref><ref id="cit0014"><label>14.</label><mixed-citation publication-type="confproc"><person-group person-group-type="author"><collab>EAU Guidelines</collab></person-group>. <article-title>Edn</article-title>. In: <conf-name>Presented at the EAU Annual Congress Paris 2024</conf-name>. <comment>ISBN 978&#8211;94&#8211;92671&#8211;23&#8211;3</comment>.</mixed-citation><note><p>
<bold>&#8226; The European Association of Urology (EAU) guidelines are a key reference for urologists and oncologists across Europe. The 2024 edition reflects the latest evidence-based recommendations for the diagnosis, treatment, and follow-up of RCC, incorporating data from pivotal trials like CheckMate 214. These guidelines are essential for standardizing care and ensuring best practices across clinical settings.</bold>
</p></note></ref><ref id="cit0015"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Powles</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Albiges</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Bex</surname><given-names>A</given-names></string-name>, et al</person-group>. <article-title>Renal cell carcinoma: eSMO clinical practice guideline for diagnosis, treatment and follow-up</article-title>. <source>Ann Oncol</source>. <year>2024</year>;<volume>35</volume>(<issue>8</issue>):<fpage>692</fpage>&#8211;<lpage>706</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.annonc.2024.05.537</pub-id><pub-id pub-id-type="pmid">38788900</pub-id></mixed-citation><note><p>
<bold>&#8226; These are the official clinical practice guidelines from the European Society for Medical Oncology (ESMO). They provide expert consensus and evidence-based recommendations for the management of RCC, including first-line treatment strategies, follow-up protocols, and patient selection criteria. This publication is particularly important for aligning clinical decisions with international standards and ensuring high-quality care.</bold>
</p></note></ref><ref id="cit0016"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>M&#233;ndez-Vidal</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>L&#225;zaro Quintela</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Lainez-Milagro</surname><given-names>N</given-names></string-name>, et al</person-group>. <article-title>Seom Sogug clinical guideline for treatment of kidney cancer (2022)</article-title>. <source>Clin Transl Oncol</source>. <year>2023</year>;<volume>25</volume>(<issue>9</issue>):<fpage>2732</fpage>&#8211;<lpage>2748</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s12094-023-03276-5</pub-id><pub-id pub-id-type="pmid">37556095</pub-id><pub-id pub-id-type="pmcid">PMC10425490</pub-id></mixed-citation></ref><ref id="cit0017"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Maroun</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Maunoury</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Benjamin</surname><given-names>L</given-names></string-name>, et al</person-group>. <article-title>In-hospital economic burden of metastatic renal cell carcinoma in France in the era of targeted therapies: analysis of the French national hospital database from 2008 to 2013</article-title>. <source>PLOS ONE</source>. <year>2016</year>;<volume>11</volume>(<issue>9</issue>):<fpage>e0162864</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0162864</pub-id><pub-id pub-id-type="pmid">27649305</pub-id><pub-id pub-id-type="pmcid">PMC5029808</pub-id></mixed-citation></ref><ref id="cit0018"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Maroun</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Mitrofan</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Benjamin</surname><given-names>L</given-names></string-name>, et al</person-group>. <article-title>Real life patterns of care and progression free survival in metastatic renal cell carcinoma patients: retrospective analysis of cross-sectional data</article-title>. <source>BMC Cancer</source>. <year>2018</year>;<volume>18</volume>(<issue>1</issue>):<fpage>214</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12885-018-4117-z</pub-id><pub-id pub-id-type="pmid">29466966</pub-id><pub-id pub-id-type="pmcid">PMC5822611</pub-id></mixed-citation></ref><ref id="cit0019"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cairns</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Srivastava</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Grizzle</surname><given-names>WE</given-names></string-name></person-group>. <article-title>Renal cell carcinoma</article-title>. <source>Cancer Biomark</source>. <year>2010</year>;<volume>9</volume>(<issue>1&#8211;6</issue>):<fpage>461</fpage>&#8211;<lpage>473</lpage>. doi: <pub-id pub-id-type="doi">10.3233/CBM-2011-0176</pub-id><pub-id pub-id-type="pmid">22112490</pub-id><pub-id pub-id-type="pmcid">PMC3308682</pub-id></mixed-citation></ref><ref id="cit0020"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rini</surname><given-names>BI</given-names></string-name>, <string-name name-style="western"><surname>Plimack</surname><given-names>ER</given-names></string-name>, <string-name name-style="western"><surname>Stus</surname><given-names>V</given-names></string-name>, et al</person-group>. <article-title>Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma</article-title>. <source>N Engl J Med</source>. <year>2019</year>;<volume>380</volume>(<issue>12</issue>):<fpage>1116</fpage>&#8211;<lpage>1127</lpage>. doi: <pub-id pub-id-type="doi">10.1056/NEJMoa1816714</pub-id><pub-id pub-id-type="pmid">30779529</pub-id></mixed-citation></ref><ref id="cit0021"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Choueiri</surname><given-names>TK</given-names></string-name>, <string-name name-style="western"><surname>Powles</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Burotto</surname><given-names>M</given-names></string-name>, et al</person-group>. <article-title>Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma</article-title>. <source>N Engl J Med</source>. <year>2021</year>;<volume>384</volume>(<issue>9</issue>):<fpage>829</fpage>&#8211;<lpage>841</lpage>. doi: <pub-id pub-id-type="doi">10.1056/NEJMoa2026982</pub-id><pub-id pub-id-type="pmid">33657295</pub-id><pub-id pub-id-type="pmcid">PMC8436591</pub-id></mixed-citation></ref><ref id="cit0022"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Powles</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Plimack</surname><given-names>ER</given-names></string-name>, <string-name name-style="western"><surname>Souli&#232;res</surname><given-names>D</given-names></string-name>, et al</person-group>. <article-title>Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial</article-title>. <source>Lancet Oncol</source>. <year>2020</year>;<volume>21</volume>(<issue>12</issue>):<fpage>1563</fpage>&#8211;<lpage>1573</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S1470-2045(20)30436-8</pub-id><pub-id pub-id-type="pmid">33284113</pub-id></mixed-citation></ref><ref id="cit0023"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Stellato</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Santini</surname><given-names>D</given-names></string-name></person-group>. <article-title>ImmuneOncology-tyrosine kinase inhibitors combination, sometimes less is more</article-title>. <source>Int Immunopharmacol</source>. <year>2021</year>;<volume>98</volume>:<fpage>107673</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.intimp.2021.107673</pub-id><pub-id pub-id-type="pmid">33935023</pub-id></mixed-citation></ref><ref id="cit0024"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bolek</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Yeked&#252;z</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>&#220;r&#252;n</surname><given-names>Y</given-names></string-name></person-group>. <article-title>Combination therapies in patients with favorable risk metastatic renal cell carcinoma: a systematic review and meta-analysis</article-title>. <source>Cancer Treat Rev</source>. <year>2024</year>;<volume>122</volume>:<fpage>102667</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ctrv.2023.102667</pub-id><pub-id pub-id-type="pmid">38101099</pub-id></mixed-citation></ref><ref id="cit0025"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Motzer</surname><given-names>RJ</given-names></string-name>, <string-name name-style="western"><surname>Tannir</surname><given-names>NM</given-names></string-name>, <string-name name-style="western"><surname>McDermott</surname><given-names>DF</given-names></string-name>, et al</person-group>. <article-title>Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma</article-title>. <source>N Engl J Med</source>. <year>2018</year>;<volume>378</volume>(<issue>14</issue>):<fpage>1277</fpage>&#8211;<lpage>1290</lpage>. doi: <pub-id pub-id-type="doi">10.1056/NEJMoa1712126</pub-id><pub-id pub-id-type="pmid">29562145</pub-id><pub-id pub-id-type="pmcid">PMC5972549</pub-id></mixed-citation></ref><ref id="cit0026"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Motzer</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Alekseev</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Rha</surname><given-names>SY</given-names></string-name>, et al</person-group>. <article-title>Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma</article-title>. <source>N Engl J Med</source>. <year>2021</year>;<volume>384</volume>(<issue>14</issue>):<fpage>1289</fpage>&#8211;<lpage>1300</lpage>. doi: <pub-id pub-id-type="doi">10.1056/NEJMoa2035716</pub-id><pub-id pub-id-type="pmid">33616314</pub-id></mixed-citation></ref></ref-list></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>